Non-Small-Cell Lung Cancer: Practical Guidance for a Rapidly Evolving Treatment Paradigm

Review the latest data and expert guidance on managing patients with NSCLC. This comprehensive program features clinical commentaries, a downloadable patient communication resource, updates to the online, interactive treatment decision support tools, and a text-based module along with downloadable slides.
Matthew Gubens, MD, MS
Leora Horn, MD, MSc, FRCPC
Melissa L. Johnson, MD
Stephen V. Liu, MD
Joel Neal, MD, PhD
Karen L. Reckamp, MD, MS
H. Jack West, MD

Text Module

Review expert insights on the latest clinical data informing optimal management of patients with advanced NSCLC using targeted agents and immune checkpoint inhibitors.

Matthew Gubens, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 23, 2020 Expired: June 22, 2021

Downloadable Slideset

Download these slides providing the latest on the rapidly evolving treatment paradigm for patients with advanced NSCLC

Matthew Gubens, MD, MS Released: June 23, 2020

ClinicalThought

How do you treat patients with advanced NSCLC in the era of immunotherapy? In this commentary, Dr. Gubens discusses the latest data on frontline combination regimens using immunotherapy for the treatment of advanced NSCLC.

Matthew Gubens, MD, MS Released: December 30, 2019

How do you manage patients with advanced squamous NSCLC in the era of immunotherapy? In this commentary, H. Jack West, MD, discusses the latest treatment options for advanced squamous NSCLC involving immune checkpoint inhibitors.

H. Jack West, MD Released: February 24, 2020

To benefit from targeted therapies for patients with advanced NSCLC, it is imperative that clinicians use biomarker testing to identify potential actionable gene aberrations. In this commentary, Joel Neal, MD, PhD, discusses his approach to this dynamic aspect of clinical care.

Joel Neal, MD, PhD Released: May 11, 2020

The combination of nivolumab and ipilimumab, with or without chemotherapy, is now approved for advanced NSCLC. Read my thoughts on the rationale for these approvals and how to integrate these regimens into clinical practice.

Stephen V. Liu, MD Released: July 6, 2020

Interactive Decision Support Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with NSCLC with those of 5 renowned experts.

Matthew Gubens, MD, MS Leora Horn, MD, MSc, FRCPC Melissa L. Johnson, MD Karen L. Reckamp, MD, MS H. Jack West, MD Released: June 24, 2020

PDF

Download this PDF resource to aid treatment discussions with your patients diagnosed with advanced NSCLC including capturing their input on goals and preferences.

Released: July 24, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Grace Logo
Supported by educational grants from
Bristol-Myers Squibb
Celgene Corporation
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?